CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial

PURPOSE: Patients with B-cell acute lymphoblastic leukemia who experience relapse after or are resistant to CD19-targeted immunotherapies have limited treatment options. Targeting CD22, an alternative B-cell antigen, represents an alternate strategy. We report outcomes on the largest patient cohort...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Clin Oncol
Egile Nagusiak: Shah, Nirali N., Highfill, Steven L., Shalabi, Haneen, Yates, Bonnie, Jin, Jianjian, Wolters, Pamela L., Ombrello, Amanda, Steinberg, Seth M., Martin, Staci, Delbrook, Cindy, Hoffman, Leah, Little, Lauren, Ponduri, Anusha, Qin, Haiying, Qureshi, Haris, Dulau-Florea, Alina, Salem, Dalia, Wang, Hao-Wei, Yuan, Constance, Stetler-Stevenson, Maryalice, Panch, Sandhya, Tran, Minh, Mackall, Crystal L., Stroncek, David F., Fry, Terry J.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Clinical Oncology 2020
Gaiak:
ORIGINAL REPORTS
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7280047/
https://ncbi.nlm.nih.gov/pubmed/32286905
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.03279
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak